glp 1 vs sglt2 diabetes In older adults with type 2 (T2D), the initiation of GLP-1 receptor agonists drugs such as DPP-4 and inhibitors was associated with an 11% increased risk for fragility fractures Summary of cardiovascular outcome trials

Medicaid spending on GLP-1s hit $3.9 billion in 2023, and Medicare Part D spending on three GLP-1s hit $5.7 billion in 2022, per data from health policy research firm KFF

Still, the contraindication for those with familial MTC or MEN2 persists, as those individuals already are at high risk genetically and were excluded from trials

We collaborate closely with our distributors to equip them with the necessary resources for success in their respective markets

In a rat model, naringenin treatment following TBI elevated glutathione peroxidase and superoxide dismutase activity while reducing malondialdehyde levels in the hippocampus (Long et al., 2020)